Author

Mehrdad Rakaee

Harvard UniversityORCID 0000-0002-9080-0153Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Organism:human· 2 Approach:statistical model· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Assay:clinical cohort / trial· 1 Approach:experimental assay· 1

Frequent Co-Authors

Ahmed Omar KasebiD· 1 shared Ailin Han· 1 shared Alessandro ParisiiD· 1 shared Alexander L Gusev· 1 shared Amin H. NassariD· 1 shared Andrea DalbeniiD· 1 shared Antonio D’AlessioiD· 1 shared Anwaar SaeediD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Ahmed Omar KasebORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

DPP9-mediated inflammasome repression protects against checkpoint inhibitor lung toxicity

J. Richard Brewer, Ailin Han, Amin H. Nassar, Elias Bou Farhat, Holly N. Blackburn, Tianli Xiao, Haris Mirza, Walter K. Mowel, Esen Sefik, Saskia Hartner, Michael Chiorazzi, Takeshi Ito, Min Hee Oh, Matthew Z. Madden, Athreya S Rangavajhula, , Richard Anthony Flavell

The paper identifies DPP9 as a genetic susceptibility gene for checkpoint inhibitor pneumonitis and shows IL-18 blockade could be a therapeutic strategy.

bioRxiv · Jul 3, 2026 · PreprintImmunology

Clinical and molecular characterisation of primary refractoriness to atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma.

Pasquale Lombardi, Erik Ramon‐Gil, Leonardo Brunetti, Giulia Francesca Manfredi, George Merces, Claudia Angela Maria Fulgenzi, Antonio D’Alessio, Aria Torkpour, Ciro Celsa, Bernardo Stefanini, Hannah Yang, Fionnuala Crowley, Thomas Urban Marron, Anwaar Saeed, Matthias Pinter, , David James Pinato

This study identifies clinical and molecular features of primary refractoriness to atezolizumab plus bevacizumab in HCC, showing poor outcomes and an immunosuppressive tumor microenvironment.

bioRxiv · Jul 8, 2025 · PreprintCancer Biology